AZN — AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: GB
- Exchange: NYSE
- Employees: 94,300
- Website: https://www.astrazeneca.com
Latest SEC filings for AZN
- 6-K — 2026-10-22
- 6-K — 2026-10-05
- 6-K — 2026-10-02
- 6-K — 2026-10-01
- 6-K — 2026-10-01
- 6-K — 2026-09-29
- 6-K — 2026-09-23
- 6-K — 2026-09-21
- 6-K — 2026-09-21
- 6-K — 2026-09-18
Latest AZN news
- — Why Healthcare ETFs Are Hovering Around One-Year Highs (Zacks Investment Research)
- — AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy (Zacks Investment Research)
- — Summit Expands Ivonescimab Development Into Biliary Tract Cancer (Zacks Investment Research)
- — Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight (GlobeNewswire Inc.)
- — Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? (Zacks Investment Research)
- — Biotech ETF (BBH) Hits New 52-Week High (Zacks Investment Research)
- — Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? (The Motley Fool)
- — GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth (Zacks Investment Research)
- — AstraZeneca and Oracle strike AI collaboration to speed up clinical trials (seekingalpha_market)
- — The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology (Zacks Investment Research)
Educational tool only — not investment advice.